ArticleClinical and translational allergy2019
Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations.
Article in Clinical and translational allergy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Application of type 2 inflammation-related biomarkers in risk prediction models for acute exacerbations in adult asthma: a systematic review.Frontiers in medicine · 2026Pooled it
- Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling of Dupilumab on Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEVCPT: pharmacometrics & systems pharmacology · 2025Trial
- A Comprehensive Analysis of the Stability of Blood Eosinophil Levels.Annals of the American Thoracic Society · 2021Trial
- Fractional exhaled nitric oxide and blood eosinophils in relation to lung function, allergy and nasal polyps in asthma.The journal of allergy and clinical immunology. Global · 2026Article
- Biomarker profile and disease burden associated with intermittent and long-term oral corticosteroid use in patients with severe asthma prior to biologic initiation in real-life (STAR).The World Allergy Organization journal · 2025Article
- Predictors of asthma exacerbation between high and low blood eosinophil counts.ERJ open research · 2025Article
- Identification of bronchial epithelial genes associated with type 2 eosinophilic inflammation in asthma.The Journal of allergy and clinical immunology · 2025Article
- Precision Medicine in Asthma: The Role of Biomarkers.ImmunoTargets and therapy · 2025Review
- Type-2 Inflammation in Health and Disease: Prevalence, Risk Factors and Multimorbidity.Journal of clinical medicine · 2024Article
- Endotyping Chronic Respiratory Diseases: T2 Inflammation in the United Airways Model.Life (Basel, Switzerland) · 2024Review
- Biologic therapies for severe asthma with persistent type 2 inflammation.Australian prescriber · 2024Review
- Fractional exhaled nitric oxide (FeNO): the future of asthma care?The British journal of general practice : the journal of the Royal College of General Practitioners · 2023Article
- Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma.ERJ open research · 2023Article
- Update on the Role of FeNO in Asthma Management.Diagnostics (Basel, Switzerland) · 2023Review
- Distribution of type 2 biomarkers and association with severity, clinical characteristics and comorbidities in the BREATHE real-life asthma population.ERJ open research · 2023Article
- Clinical Trial Design Innovations for Precision Medicine in Asthma.Advances in experimental medicine and biology · 2023Article
- Fractional nitric oxide measurement in exhaled air (FeNO): perspectives in the management of respiratory diseases.Therapeutic advances in chronic disease · 2023Review
- Comparison between clinical trials and real-world evidence studies on biologics for severe asthma.The Journal of international medical research · 2022Review
- Epithelial Autoantigen-Specific IgG Antibody Enhances Eosinophil Extracellular Trap Formation in Severe Asthma.Allergy, asthma & immunology research · 2022Article
- Critical evaluation of asthma biomarkers in clinical practice.Frontiers in medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBlood eosinophil count (BEC) and fractional exhaled nitric oxide (FeNO) concentration are established biomarkers in asthma, associated particularly with the risk of exacerbations. We evaluated the relationship of BEC and FeNO as complementary and independent biomarkers of severe asthma exacerbations.
methodsThis observational study included data from the Optimum Patient Care Research Database. Asthma patients (18-80 years) with valid continuous data for 1 year before FeNO reading, ≥ 1 inhaled corticosteroid prescription, and BEC recorded ≤ 5 years before FeNO reading were separated into cohorts. Categorisation 1 was based on the American Thoracic Society criteria for elevated FeNO concentration (high: ≥ 50 ppb; non-high: < 25 ppb) and BEC (high: ≥ 0.300 × 10
resultsIn categorisation 1, patients with either high FeNO or high BEC (n = 200) had a numerically greater exacerbation rate (unadjusted rate ratio, 1.31 [95% confidence interval: 0.97, 1.76]) compared with patients in the reference group. Combination of high FeNO and high BEC (n = 27) resulted in a significantly greater exacerbation rate (3.67 [1.49, 9.04]). Similarly, for categorisation 2, when both biomarkers were raised (n = 53), a significantly greater exacerbation rate was observed (1.72 [1.00, 2.93]).
conclusionThe combination of high FeNO and high BEC was associated with significantly increased severe exacerbation rates in the year preceding FeNO reading, suggesting that combining FeNO and BEC measurements in primary care may identify asthma patients at risk of exacerbations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.